Animal rights activist who targeted Novartis convicted in U.K.; Adcock admits 'extreme pressure' on profits; Recipharm plans share sale in Stockholm;

@FiercePharma: Statins and muscle aches are unrelated. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Article | Follow @TracyStaton

@EricPFierce: New purification plant is part of Novo Nordisk's $3.7B R&D push. News | Follow @EricPFierce

> The U.K. animal rights activist who targeted former Novartis ($NVS) Chairman and CEO Daniel Vasella was convicted of conspiracy to commit blackmail. Report

> South Africa's Adcock Ingram said its quarterly profits are under "extreme pressure" as consumers cut back on medications. Report

> The Swedish drugmaker Recipharm plans to sell shares in Stockholm, hoping to raise up to 898 million crowns, or about $142 million. Report

> Germany-based Bayer says it's looking at expanding further in emerging markets, particularly in Africa. Report

> Sir Andrew Dillon, CEO of the U.K.'s cost-effectiveness agency, called for more data transparency in pharma to improve the industry's relationship with healthcare providers. Report

Medical Device News

@FierceMedDev: Here's our latest FierceDiagnostics, with news on concussion biomarkers, autism tests and more. Newsletter | Follow @FierceMedDev

@MarkHFierce: A European VC firm is raising $ for a new fund that will target, in part, Dx and device companies. Story | Follow @MarkHFierce

@MichaelGFierce: NASA tech makes space-age microcapsules for cancer drug delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Good news for chocolate lovers: Bacteria in the gut can eat up cocoa and turn it into compounds that help the heart. Article | Follow @EmilyWFierce

> C.R. Bard enrolls first patient in a new U.S. clinical trial of its drug-coated balloon. News

> Augmedix grabs $3.2M for Google Glass-enabled medical records physician tool. More

> Flagging Smiths Medical, soaring pound weigh down Smiths Group earnings. Story

Biotech News

@FierceBiotech: Novo touts a PhIII hemophilia win as it chases Biogen, Bayer. Story | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers partner Alder Bio looking for $115M IPO haul - clazakizumab and migraine drug ALD403. More | Follow @JohnCFierce

@DamianFierce: Proteon sets out on its own after Novartis waves off a $550M deal. News | Follow @DamianFierce

@GalenMoore: Exact Sciences' at-home test for colon cancer is nearly as effective as a colonoscopy. Read more at Bloomberg | Follow @GalenMoore

> The FDA vs. the flash mob: Hard questions as parents demand unproven drugs. More

> A renal cancer study fails and stock plunges, but Bionomics stays upbeat. Story

Drug Delivery News

> MedImmune inks licensing deal with Bioasis for brain delivery platform. News

> GenSpera enrolls brain cancer mid-stage trial with 'grenade' delivery. Story

> NASA tech makes space-age microcapsules for cancer drug delivery. Story

> Harvard scientists fold DNA to make cages for drug delivery. Article

> CeloNova wins a U.S. exemption trial for its nano-coated stent. News

> Oral drugs derived from snail venom could offer less invasive pain management. Brief

Diagnostics News

> Waters Corp. will help develop a blood-based biomarker test to predict the risk of premature birth. Story

> SynapDx and the Broad Institute link to use next-gen sequencing for better autism tests. News

> Quanterix diagnostic spotted a key concussion biomarker in blood. Article

> Is diagnostics maker Corgenix looking to sell itself? Story

> For 2014, Trovagene plots multiple ways to expand the reach of its Dx cancer tech. Story

> Federal funding drops are forcing layoffs at the Broad Institute's genome sequencing arm. Brief

Pharma Marketing News

> They're no Coca-Cola, but top biopharma brands Pfizer, Biogen and Merck still worth billions. Report

> Roche's Perjeta proves a fast fave with cancer docs, but Kadcyla's a speed racer. Story

> McKinsey's four drug launch flavors: Good, bad, ugly and misguided. Story

> Pfizer's impressive Prevnar data isn't enough to win billions in adult sales. Analysis

> For once, the FDA writes up pharma for a simple Facebook violation. News

> Probe finds Novartis not guilty of 'undue influence' at Canadian university eye clinic. Brief

And Finally... A measles outbreak in New York City may have been spread by medical workers. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.